Published in Nat Immunol on May 23, 2016
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
IL-15 sustains IL-7R-independent ILC2 and ILC3 development. Nat Commun (2017) 0.77
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol (2017) 0.76
Type 1 Innate Lymphoid Cell Biology: Lessons Learnt from Natural Killer Cells. Front Immunol (2016) 0.76
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. Oncoimmunology (2017) 0.75
Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival. J Exp Med (2017) 0.75
Unchaining NK cell-mediated anticancer immunosurveillance. Nat Immunol (2016) 0.75
Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling. Elife (2017) 0.75
STATs in NK-Cells: The Good, the Bad, and the Ugly. Front Immunol (2017) 0.75
Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med (2017) 0.75
Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci (2017) 0.75
Tumour immunology: A checkpoint for NK cells. Nat Rev Immunol (2016) 0.75
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Front Immunol (2017) 0.75
SOCS molecules: the growing players in macrophage polarization and function. Oncotarget (2017) 0.75
The role of dendritic cells in cancer. Semin Immunopathol (2016) 0.75
Immune Checkpoint in Glioblastoma: Promising and Challenging. Front Pharmacol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol (2008) 38.00
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Universal sample preparation method for proteome analysis. Nat Methods (2009) 16.88
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res (2011) 14.82
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics (2014) 5.09
SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol (2003) 4.90
Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A (1998) 4.38
SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell (1999) 4.29
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A (1999) 3.91
A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J (1995) 3.78
The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J (1999) 3.77
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood (1997) 3.08
Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol (2007) 2.66
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol (2014) 2.59
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity (2012) 2.30
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc Natl Acad Sci U S A (2011) 2.01
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol (2015) 1.68
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med (2015) 1.58
Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A (2006) 1.57
SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol (2013) 1.38
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36
The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat Immunol (2013) 1.26
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 1.25
STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J Immunol (2006) 1.22
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med (2014) 1.21
CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. J Biol Chem (1999) 1.21
Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev (2013) 1.20
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res (2014) 1.19
Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer (2016) 1.08
Accurate protein complex retrieval by affinity enrichment mass spectrometry (AE-MS) rather than affinity purification mass spectrometry (AP-MS). Mol Cell Proteomics (2014) 1.07
Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol (2014) 1.07
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun (2014) 1.03
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discov (2016) 0.92
Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance. Transplant Proc (2012) 0.91
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett (2009) 0.89
Using peptide array to identify binding motifs and interaction networks for modular domains. Methods Mol Biol (2009) 0.88
In vitro JAK kinase activity and inhibition assays. Methods Mol Biol (2013) 0.88
The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol Cell Biol (2014) 0.88
Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS One (2013) 0.85
Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech (2015) 0.83
Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer. Cancer Immunol Res (2015) 0.79
Analysis of Suppressor of Cytokine Signalling (SOCS) gene expression by real-time quantitative PCR. Methods Mol Biol (2013) 0.78
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res (2017) 0.80
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol (2017) 0.76
Innate Allorecognition Results in Rapid Accumulation of Monocyte-Derived Dendritic Cells. J Immunol (2016) 0.76
Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. Nat Commun (2020) 0.75